The Cooper Companies Reports First Quarter 2005 Results
The Cooper Companies Reports First Quarter 2005 Results
- Revenue Ahead 35% to $147.9 Million
-
EPS 58 Cents Before Nonrecurring Items; Reported EPS 48 Cents
LAKE FOREST, Calif., March 9, 2005 (PRIMEZONE) -- The Cooper Companies, Inc. (NYSE:COO) today reported results for its fiscal first quarter ended January 31, 2005. On January 6, 2005, Cooper completed the acquisition of Ocular Sciences, Inc. and Ocular's results are included from that date forward.
First Quarter Highlights
-- Reported revenue $147.9 million, 35% above the first quarter of
2004, 31% in constant currency. Including Ocular's sales for
the first week in January 2005, first quarter revenue would
have been $151.2 million.
-- Operating income, before nonrecurring acquisition and
restructuring expenses, $30.8 million, 24% above the first
quarter of 2004; with one-time charges included, $27.7 million
or 11% above last year's first quarter.
-- EPS 58 cents before nonrecurring acquisition and restructuring
costs; reported EPS 48 cents.
-- Cash flow (pretax income from continuing operations plus
depreciation and amortization before nonrecurring acquisition
and restructuring costs) per share 90 cents, up from 76 cents
in the first quarter of 2004; trailing twelve months $3.64.
Revenue and Earnings Per Share Guidance
-- Cooper expects fiscal 2005 revenue of $867 million to $879
million, assuming no major changes in exchange rates, and
earnings per share of $3.08 to $3.18, before nonrecurring
costs for merger related accounting and restructuring
charges, and assuming an effective tax rate of 21%. This
revenue guidance is $3 million below the mid point of the
Company's projections issued in January 2005 because revenue
from the acquired Ocular business is only included from
January 6, 2005, not from January 1 as the earlier guidance
assumed. EPS guidance for the remaining three quarters of
2005 is unchanged.
-- With the same adjustment to reflect the inclusion of Ocular's
business from January 6, 2005 not January 1, 2005, CooperVision
(CVI), the Company's contact lens business, now expects fiscal
2005 revenue of $752 million to $761 million, assuming no major
changes in foreign exchange rates. CooperSurgical (CSI), the
Company's women's healthcare medical device business, expects
revenue of $115 million to $118 million for fiscal 2005,
unchanged from January guidance.
-- For the second fiscal quarter, Cooper expects revenue to range
from $222 million to $226 million-$195 million to $198 million
for CVI and $27 million to $28 million for CSI-with earnings
per share ranging from 72 cents to 75 cents before
nonrecurring acquisition and restructuring costs. This guidance
is unchanged from the Company's January 2005 projections.
Reported P&L Highlights ($'s in millions)
-----------------------------------------
---------------------------------------------------------------------
Three Months Ended January 31,
---------------------------------------------------------------------
Revenue Operating Income
---------------------------------------------------------------------
% % % Revenue % Revenue
2005 2004 Inc. 2005 2004 Inc. 2005 2004
---------------------------------------------------------------------
CVI $121.4 $ 87.0 39% $ 30.9(a) $ 22.6 37% 25% 26%
CSI 26.5 22.7 17% 3.7 5.4 (31)% 14% 24%
------ ------ ------ ------
Subtotal 147.9 109.7 35% 34.6 28.0 24% 23% 26%
Corporate
Expense -- -- -- (3.8) (3.1) -- -- --
------ ------ ------ ------
---------------------------------------------------------------------
TOTAL $147.9 $109.7 35% $ 30.8 $ 24.9 24% 21% 23%
====== ====== ====== ======
---------------------------------------------------------------------
(a)Before nonrecurring charges for merger related accounting and
restructuring of $3.1 million
First Quarter 2005 Revenue and Expense Summary
Cooper's first quarter revenue of $147.9 million was 35% above last year's first quarter, 31% in constant currency. Including Ocular's sales for the first week in January 2005, first quarter revenue would have been $151.2 million.
Gross margin, before nonrecurring acquisition and restructuring costs, was 64%, unchanged from last year's first quarter; 62% including one-time charges.
Selling, general and administrative expense grew 39% and increased to 41% of revenue from 39% in last year's first quarter.
Corporate expenses, which increased to $3.8 million, were 23% over the first quarter of 2004. These include added costs due to the Ocular acquisition, increased costs to comply with new corporate governance requirements and continuing costs to maintain Cooper's global trading arrangement.
In 2005, Cooper expects an aggregate increase in costs and expenses to operate the combined Cooper and Ocular businesses. This increase, however, should be substantially lower than the aggregate amount of costs and expenses that would have been incurred by Cooper and Ocular had they continued to operate as separate businesses. Corporate governance expense will also continue to rise, while expenses for the global trading arrangement will flatten.
First quarter 2005 research and development expense was $2.8 million, up 86% over the first quarter of 2004. CVI's research and development activities, now augmented by Ocular's strong research pipeline, include programs to develop two-week disposable and continuous wear silicone hydrogel lenses, a disposable multifocal toric, a daily wear lens incorporating the Proclear® lens material and products that address specific market needs in the Asia-Pacific region.
Operating income before one-time charges grew 24%, 21% of revenue versus 23% in last year's first quarter. With one-time charges included, operating income was 19% of revenue.
Reflecting the added debt of the Ocular acquisition, interest expense grew 149% over the first quarter of 2004.
The effective tax rate (ETR) for the quarter (provision for taxes divided by income before taxes) was 21% compared to 23% for the first quarter of 2004. The ETR for both periods represented Cooper's estimate of the ETR for each full fiscal year.
Compared to the first quarter of 2004, the number of shares used to calculate diluted earnings per share increased 9% to 39.5 million shares, primarily due to the issuance of 10.7 million shares to Ocular shareholders in January 2005.
Fiscal First Quarter 2005 Business Unit Operating Summaries ($'s in millions)
Fiscal First Quarter 2005 Business Unit Operating Summaries
($'s in millions)
-----------------------------------------------------------
---------------------------------------------------------------------
CooperVision CooperSurgical
------------------------------------------------- -------------------
2005 2005 2005(a) % % chg vs 2005 % Rev % chg
Reported One-time Rev(a) 2004(a) vs 2004
charges
------------------------------------------------- -------------------
Net sales $121.4 $ -- $121.4 100% 39% $ 26.5 100% 17%
Cost of
sales 43.7 (2.4) 41.3 34% 41% 11.9 45% 14%
------ ------ ------ ------
Gross
profit 77.7 2.4 80.1 66% 39% 14.6 55% 19%
SG&A 46.6 -- 46.6 38% 38% 9.8 37% 54%
R&D and
amortization 2.6 -- 2.6 2% 103% 1.1 4% 89%
Restructuring
costs 0.7 (0.7) -- -- -- -- -- --
------ ------ ------
Total
operating
expense 49.9 (0.7) 49.2 40% 40% 10.9 41% 57%
------ ------ ------ ------
Operating
income $ 27.8 $ 3.1 $ 30.9 26% 37% $ 3.7 14% (31)%
====== ====== ====== ======
--------------------------------------------------------------------
(a)Before nonrecurring charges for merger related accounting and
restructuring of $3.1 million
Balance Sheet and Cash Flow Highlights
-- At the end of the first fiscal quarter, Cooper's days sales
outstanding (DSO) decreased to 65 days from 69 days a year
ago. Cooper expects future DSO in the upper 60's to low 70's.
These DSO's are pro forma, calculated including Ocular's
results of operations during Cooper's first fiscal quarter of
2005.
-- Pro forma inventory months on hand was 6.8 months at the end of
the quarter, versus 7.5 months at last year's first quarter, in
line with company expectations.
-- Capital expenditures were $11.6 million in the quarter,
primarily to expand manufacturing capacity and continue the
rollout of new information systems in selected locations.
Cooper expects capital expenditures in fiscal 2005 of about
$120 million to $130 million. About 70% of this will be spent
for expanded capacity, about 20% for conversion of CVI's
products to the Gen II manufacturing platform acquired in the
Ocular acquisition and about 10% for information technology.
-- Depreciation and amortization was $7.6 million for the quarter.
CooperVision Business Details
"In our first quarter, CVI continued to outpace both the market and our competitors' results reported for the fourth calendar quarter of 2004," said A. Thomas Bender, Cooper's chief executive officer. "Specialty lenses, which include toric lenses, cosmetic lenses, multifocal lenses, continuous wear lenses and lenses for dry eye symptoms, continue to gain momentum, while our disposable spherical products, now augmented with the Ocular Sciences product line of two-week and daily wear disposable lenses, continue to capture market share. Our global toric sales, 37% of our lens business, continue to grow twice as fast as worldwide toric sales."
CVI's operating margin in the first quarter, before nonrecurring acquisition and restructuring expenses, was 26% the same as in last year's first quarter. Including one-time items, CVI's operating margin was 23%.
2004 Contact Lens Market Highlights
According to independent market research data, the worldwide contact lens market grew 13% in calendar 2004 to $4 billion -- 8% in constant currency. The soft contact lens market in the United States grew about 8% to $1.5 billion, while revenue in countries outside the United States grew about 16% to $2.5 billion.
Specialty lenses grew 17% and now account for 30% of the worldwide soft lens market. Toric lenses, the largest specialty product category, grew approximately 15% to about $560 million while the daily disposable segment grew about 20% to approximately $1.2 billion.
The Americas region, approximately $1.6 billion or 41% of the world market, grew approximately 8%. Japan and the Pacific Rim countries, approximately $1.2 billion or 30% of the world market, grew approximately 15%. Europe, about $1.2 billion or 29% of the market, grew approximately 16%.
CooperVision, combined with Ocular, estimates its worldwide market share at 18%, making it the world's third leading contact lens company in terms of revenue. It now accounts for over 40% of worldwide toric revenues.
First Quarter CooperVision Worldwide Highlights
-- CVI's worldwide revenue of $121.4 million grew 39% over last
year's first quarter-34% in constant currency. Including
Ocular's sales for the first week in January 2005, first
quarter CVI revenue was $124.7 million.
-- CVI's specialty lenses, which include toric lenses, cosmetic
lenses, multifocal lenses and lenses for dry eye symptoms, grew
29% and accounted for 58% of its soft lens business.
-- CVI's toric lens revenue increased 28% and accounted for about
37% of its contact lens revenue. Disposable torics grew 44% and
account for about 80% of total toric revenue.
-- Disposable spheres, including Proclear(r), and Biomedics 55
Premier(tm) aspheric and Biomedics(r) daily disposable grew 55%, and
account for 90% of CVI's spherical lens sales. Daily
disposable lenses, sold primarily under the Biomedics(r) and
Aquair(r) brand names in Japan and Europe, had January revenue
of about $6 million.
-- The Proclear(r) line of disposable spheres, torics and multifocals
continues to show strong growth-up 43% for the quarter-and now
accounts for 20% of CVI's global revenue.
-- CVI's disposable sphere, toric, cosmetic and multifocal lenses
grew 51% during the quarter, and represent about 86% of its
business.
First Quarter CVI Geographic Revenue Highlights
-- In the Americas region, which accounts for 50% of CVI's contact
lens business, revenue grew 25%-24% in constant currency-led by
Proclear(r) products, up 46%, and toric lenses up about 21%. CVI's
two-week and monthly disposable toric franchise grew 41% and
now account for 73% of its toric business.
-- European lens revenue, 40% of CVI's total revenue, grew 41%-31%
in constant currency-lead by toric lenses, up 51%, and Proclear(r)
products, up 40%.
-- Asia-Pacific revenue grew 170% and now represents about 10% of
CVI's worldwide contact lens business led by daily disposable
lens revenue.
CVI First Quarter Expenses
CVI's gross margin before nonrecurring items was 66% of revenue, the same as in last year's first quarter. Gross profit with one-time charges included was 64%, primarily due to the cost of stepping up Ocular's inventory by $15 million to reflect manufacturing profit acquired, which will be written off over 7 months.
CVI's SG&A expense grew 38% during the quarter compared to revenue growth of 39%.
Research and development expense was $2 million, up 96% over the first quarter of 2004. CVI's research and development activities, now augmented by Ocular's strong research pipeline, include programs to develop two-week disposable and continuous wear silicone hydrogel lenses, a daily disposable lens incorporating the Proclear® lens material and products that address specific needs in the Asia-Pacific market.
The effect of currency on operating income in the quarter was not significant.
CooperSurgical Business Details
Revenue at CooperSurgical, Cooper's women's healthcare medical device business, grew 17% over last year's first quarter to $26.5 million with organic growth of 10%.
CSI's operating income declined 31% and was 14% of revenue as marketing expenses accelerated for programs designed to increase the organic growth of its business. These programs will focus on CSI's products in the incontinence, infertility and female sterilization markets using its restructured sales force of 175 independent and direct sales representatives.
Earnings Per Share
All per share amounts in this news release refer to diluted per share amounts. Cooper has restated its diluted earnings per share beginning in the third fiscal quarter of 2003 to reflect the accounting change for contingent convertible debentures.
Non-GAAP Financial Measures (In thousands, except per share amounts)
In this news release, we report Cooper's "cash flow per share" for the first quarter of fiscal 2005 and 2004 as 90 cents and 76 cents, respectively, and our cash flow per share for the twelve months ended January 31, 2005 as $3.64.
Although "cash flow per share" is a non-GAAP financial measure, we disclose it because we believe it is the most appropriate measure of Cooper's liquidity and financial strength, particularly when calculated consistently over time. In Cooper's case, cash flow per share is more informative than the more common non-GAAP measure of liquidity called "earnings before interest, taxes, depreciation and amortization" (EBITDA) because, unlike most companies, Cooper does not expect to pay federal income taxes until after 2007, when it expects to exhaust the usage of its U.S. net operating loss carryforwards. Cooper has a significant competitive advantage, as most companies expend a large portion of their pretax profits on taxes. Readers should understand this and judge our financial strength accordingly.
To calculate "cash flow per share," we add back non-cash charges for depreciation, amortization and nonrecurring acquisition and restructuring costs to income before income taxes, and then divide the result by the average number of shares used to calculate diluted earnings per share. In the table below, we reconcile earnings per share (the closest GAAP disclosure) to "cash flow per share" for all periods reported using the same diluted per share figures. To calculate "cash flow per share" for the trailing twelve months, we add the result for fiscal first quarter 2005 to fiscal year 2004 cash flow per share then subtract fiscal first quarter 2004.
Q1 Q1 Twelve Months Twelve Months
2005 2004 Ended 10/31/04 Ended 1/31/05
--------------------------------------------
Income for calculating
earnings per share $ 19,010 $ 18,878 $ 94,920
Add:
Income taxes 4,873 5,483 19,664
Depreciation 6,687 3,244 13,599
Amortization 888 345 2,052
Nonrecurring
acquisition and
restructuring
expenses 4,712 -- --
Less: Interest charge
applicable to
convertible debt, net
of tax 524 523 2,095
---------------------------
"Cash flow" $ 35,646 $ 27,427 $128,140
Earnings per share $ 0.48 $ 0.52 $ 2.59
===========================
Cash flow per share $ 0.90 $ 0.76 $ 3.50 $ 3.64
============================================
Number of shares used
to compute diluted
earnings per share 39,479 36,133 36,613
===========================
Conference Call
The Cooper Companies will hold a conference call to discuss its first quarter results today at 2 p.m. Pacific Standard Time. To access the live call, dial 1-888-396-2386. A replay will be available at 1-888-286-8010 approximately one hour after the call ends and remain available for five days. This call will also be broadcast live on The Cooper Companies' Web site, http://www.coopercos.com and at http://www.streetevents.com.
Forward-Looking Statements
This news release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. These include certain statements about the integration of the Ocular businesses, our capital resources, performance and results of operations. In addition, all statements regarding anticipated growth in our or the combined company's revenue, anticipated market conditions, planned product launches and results of operations are forward-looking. To identify these statements look for words like "believes," "expects," "may," "will," "should," "could," "seeks," "intends," "plans," "estimates" or "anticipates" and similar words or phrases. Discussions of strategy, plans or intentions often contain forward-looking statements. Forward-looking statements necessarily depend on assumptions, data or methods that may be incorrect or imprecise and are subject to risks and uncertainties. These include the risk that the Cooper and Ocular businesses will not be integrated successfully; the risks related to the implementation of information technology systems covering the combined Cooper and Ocular businesses and any delays in such implementation which could result in management having to report a significant deficiency or material weakness in the effectiveness of the Company's internal control over financial reporting in its 2005 annual report on Form 10-K; the risk that the combined company may not continue to realize anticipated benefits from its cost-cutting measures; risk inherent in accounting assumptions made in the acquisition, the ultimate validity and enforceability of the companies' patent applications and patents and the possible infringement of the intellectual property of others.
Events, among others, that could cause our actual results and future actions of the company to differ materially from those described in forward-looking statements include major changes in business conditions, a major disruption in the operations of our manufacturing or distribution facilities, new competitors or technologies, significant delays in new product introductions, the impact of an undetected virus on our computer systems, acquisition integration delays or costs, increases in interest rates, foreign currency exchange exposure, investments in research and development and other start-up projects, dilution to earnings per share from acquisitions or issuing stock, worldwide regulatory issues, including product recalls and the effect of healthcare reform legislation, cost of complying with new corporate governance requirements, changes in tax laws or their interpretation, changes in geographic profit mix effecting tax rates, significant environmental cleanup costs above those already accrued, litigation costs including any related settlements or judgments, cost of business divestitures, the requirement to provide for a significant liability or to write off a significant asset, including impaired goodwill, changes in accounting principles or estimates, including the impact of the change in GAAP to require expensing stock options, and other events described in our Securities and Exchange Commission filings, including the "Business" section in Cooper's Annual Report on Form 10-K for the fiscal year ended October 31, 2004. We caution investors that forward-looking statements reflect our analysis only on their stated date. We disclaim any intent to update them except as required by law.
Corporate Information
The Cooper Companies, Inc. manufactures and markets specialty healthcare products through its CooperVision and CooperSurgical units. Corporate offices are in Lake Forest and Pleasanton, Calif. The World Wide Web address is www.coopercos.com. A toll free interactive telephone system at 1-800-334-1986 provides stock quotes, recent press releases and financial data.
CooperVision manufactures and markets contact lenses and ophthalmic surgery products. Headquartered in Lake Forest, Calif., it manufactures in Albuquerque, N.M., Huntington Beach, Calif., Juana Diaz, Puerto Rico, Norfolk, Va., Rochester, N.Y., Adelaide, Australia, Hamble and Hampshire England, Ligny-en-Barrios, France, Madrid, Spain and Toronto. Its Web address is www.coopervision.com.
CooperSurgical manufactures and markets diagnostic products, surgical instruments and accessories to the women's healthcare market. With headquarters and manufacturing facilities in Trumbull, Conn., it also manufactures in Pasadena, Calif., Fort Atkinson, Wis., Malmo, Sweden, Montreal and Berlin. Its Web address is www.coopersurgical.com.
FINANCIAL STATEMENTS FOLLOW
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
Consolidated Condensed Statements of Income
-------------------------------------------
(In thousands, except earnings per share amounts)
(Unaudited)
Three Months Ended
January 31,
--------------------------------
2005 2004
--------- ---------
Net sales $ 147,890 $ 109,734
Cost of sales 55,568 39,778
--------- ---------
Gross profit 92,322 69,956
Selling, general and
administrative expense 60,189 43,237
Research and
development expense 2,830 1,525
Restructuring costs 723 --
Amortization of
intangibles 888 345
--------- ---------
Operating income 27,692 24,849
Interest expense 3,719 1,491
Other income (loss),
net (614) 480
--------- ---------
Income before income
taxes 23,359 23,838
Provision for income
taxes 4,873 5,483
--------- ---------
Net income 18,486 18,355
Add interest charge
applicable to
convertible debt, net
of tax 524 523
--------- ---------
Income for calculating
earnings per share $ 19,010 $ 18,878
========= =========
Diluted earnings per
share $ 0.48 $ 0.52
========= =========
Number of shares used
to compute earnings
per share 39,479 36,133
========= =========
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
Consolidated Condensed Balance Sheets
-------------------------------------
(In thousands)
(Unaudited)
January 31, October 31,
2005 2004
---------- ----------
ASSETS
Current assets:
Cash and cash
equivalents $ 28,494 $ 39,368
Trade receivables, net 145,308 99,269
Marketable securities -- 1,829
Inventories 196,888 107,607
Deferred tax asset 30,864 20,296
Other current assets 37,416 36,129
---------- ----------
Total current assets 438,970 304,498
---------- ----------
Property, plant and
equipment, net 319,692 151,065
Goodwill 1,296,277 310,600
Other intangibles, net 60,639 31,768
Deferred tax asset 16,947 10,315
Other assets 12,990 3,315
---------- ----------
$2,145,515 $ 811,561
========== ==========
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Short-term debt $ 21,731 $ 20,871
Other current
liabilities 180,319 95,638
---------- ----------
Total current
liabilities 202,050 116,509
---------- ----------
Long-term debt 723,037 144,865
Other long-term
liabilities 9,858 --
Deferred tax liability 6,026 6,026
---------- ----------
Total liabilities 940,971 267,400
---------- ----------
Stockholders' equity 1,204,544 544,161
---------- ----------
$2,145,515 $ 811,561
========== ==========
CONTACT:
The Cooper Companies, Inc.
Norris Battin
ir@coopercompanies.com